

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01. Amended 01/01/11.

Name of entity	CLINUVEL PHARMACEUTICALS LTD
ABN	88 089 644 119

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Philippe Wolgen
Date of last notice	05 July 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust.

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct Interest (Ordinary Shares)
Nature of indirect interest (including registered holder) <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	
Date of change	18 March 2022 to 22 March 2022
No. of securities held prior to change	3,175,321 Ordinary Shares (includes 2,199,810 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust and the Performance Rights Plan Trust) 1,513,750 Unlisted Performance Rights (various milestones, expiry date 20/11/2023)
Class	Ordinary Shares
Number acquired	Nil
Number disposed	55,606

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$1,132,006.32
No. of securities held after change	3,119,715 Ordinary Shares (includes 2,199,810 Ordinary Shares beneficially held in the Clinuvel Conditional Performance Rights Scheme Trust and the Performance Rights Plan Trust) 1,513,750 Unlisted Performance Rights (various milestones, expiry date 20/11/2023)
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	On-market sale, representing 1.75% of Dr Wolgen's holdings. The disposal of shares is to meet pension planning and periodic rebalancing of family assets. Dr Wolgen does not receive annual fixed equity awards or options as part of his remuneration. Instead, performance Rights are issued after multiple years, subject to shareholder approval, and are conditional on meeting certain specified performance conditions over a long term vesting period.

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	n/a
Nature of interest	n/a
Name of registered holder (if issued securities)	n/a
Date of change	n/a
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	n/a
Interest acquired	n/a
Interest disposed	n/a

Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	n/a
Interest after change	n/a

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No. The sale was permitted by the Board under its Share Trading Policy for directors to trade during in an open period, generally limited to 4 times per annum
If so, was prior written clearance provided to allow the trade to proceed during this period?	n/a
If prior written clearance was provided, on what date was this provided?	n/a